Health and life sciences companies are short of exactly one thing: researchers who understand how evidence actually gets made and can speak to product, commercial and regulatory teams. The barrier is almost never capability. It is that the market cannot see you outside your journal.
Hi Professor,
What from research to industry has produced for academics and researchers like you:
▋
Your CV proves publication output and grant success, and says nothing about commercial judgement, so recruiters cannot place you.
You are applying into processes that were already decided informally before the listing appeared.
The language of academic rigour does not translate to product, growth or regulatory teams.
You are competing with researchers who are no better, but who have been publicly visible for two years.
Nobody in industry knows what specific problem to call you about.
Typical annual cash for a scientific advisory board seat at a venture-backed health company, often plus equity.
Common advisory equity range for a scientific advisor at an early stage company.
Hourly range for expert consulting and evidence review work in the United States.
We separate what you have done academically from what industry actually buys: trial design judgement, translational insight, regulatory literacy, evidence generation, statistical rigour.
Repositioned around a commercial problem rather than a subfield. The claim is written so a founder, a product lead and an investor each understand why you matter.
A deliberate body of writing aimed at operators: why a trial design fails, what evidence a buyer actually needs, where a translational pipeline stalls.
Scope, rate card, conflict of interest position, availability and the one page any founder or board needs to justify appointing you.
A named list of companies, funds, events and communities that fit the position, worked deliberately rather than hoped for.
Preparation for advisory calls, board interviews and offer conversations, including how to price yourself without apologising.
Two to four hours a month, plus the conversations the work produces. The point is to make those conversations happen, not to add another project to your week.
Academics who want to leave research immediately for a guaranteed role. This builds the standing that produces offers. It is not a recruitment service.
Audit, positioning and industry-facing surfaces rebuilt.
Publishing starts. Target list built and worked.
First advisory conversations and inbound approaches.
First paid engagement, seat or role, depending on the route chosen.
Deep experience with diagnostic pipelines, roughly five hundred LinkedIn connections, and a public record that mentioned none of it.
Positioned at the intersection of genomics and diagnostics, with two substantive pieces written for commercial decision makers and a worked target list.
Inbound conversations from diagnostics companies within weeks, then a scientific advisory board seat inside ninety days.
No. Most of our clients keep their post and add advisory, board or consulting income alongside it. Several use that combination as the reason companies want them.
Why an excellent CV still gets skipped.
Why doctors stop publishing after three weeks.
Why good doctors never get quoted.
Why doctors take the wrong opportunities.
Being known is not the same as being booked.
Pick a time below. Fifteen minutes, private, no pitch. We'll tell you where we think your expertise has the greatest commercial value.